Transcode Therapeutics (RNAZ) Preferred Shares (2026)
Transcode Therapeutics' (RNAZ) quarterly Preferred Shares came in at $121.0 in Q2 2026, little changed quarter-over-quarter from $121.0 in Q1 2026.
Powered by 
Analysis
Transcode Therapeutics (RNAZ) Preferred Shares (2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has reported Preferred Shares for 1 consecutive years, with $121.0 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | - |
| 10 | Transcode Therapeutics | 1.70 Mn | 1.70 Mn | - | 121.00 |